INS and Hyperglycemia: The consistent mechanism driving enfortumab vedotin–associated DKA across all these case reports was severe insulin resistance as evidenced by hyperglycemia with elevated C-peptide levels, negative diabetes antibodies, and massive insulin dose requirements, with peak doses ranging from 800 to 7200 units per day.